TNFRSF8 and Hodgkins lymphoma: In a phase I/II study completed by Voorhees et al. [69], a patient with EATL who experienced multiple relapses achieved durable remission after treatment with CD30 CAR-T cells, revealing the safety and efficacy of CD30 CAR-T cells in treating CD30-positive HL patients.